文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

泛素激活酶E1抑制剂PYR-41减轻脓毒症肺损伤

PYR-41, A Ubiquitin-Activating Enzyme E1 Inhibitor, Attenuates Lung Injury in Sepsis.
PubMed 文献 · Shock · 2018-01-01
一句话结论在脓毒症小鼠中,CLP后立即静脉注射PYR-41(5 mg/kg)可减轻炎症与肺损伤,并将10天生存率从42%提高至83%。

该研究为动物实验,探讨泛素化抑制剂PYR-41在脓毒症中的作用。在脂多糖刺激的小鼠巨噬细胞RAW264.7中,PYR-41剂量依赖性防止IκB蛋白水平下降并抑制TNF-α释放。雄性C57BL/6小鼠行盲肠结扎穿刺(CLP)诱导脓毒症,术后立即静脉注射PYR-41(5 mg/kg)或溶剂对照。CLP后20小时,PYR-41显著降低血清促炎细胞因子(TNF-α、IL-1β、IL-6)和器官损伤标志物(AST、ALT、LDH),改善肺微观结构,减少肺髓过氧化物酶活性、凋亡细胞数和caspase-3降解,并恢复肺IκB蛋白水平、抑制肺内细胞因子、趋化因子和炎症介质表达。PYR-41将脓毒症小鼠10天生存率从42%显著提高至83%。作者认为,靶向泛素化以抑制NF-κB活化可能是脓毒症治疗的潜在策略。

要点

  • 在CLP脓毒症小鼠中,术后立即静脉注射PYR-41(5 mg/kg)使10天生存率从42%提高至83%。
  • CLP后20小时,PYR-41显著降低血清TNF-α、IL-1β、IL-6及AST、ALT、LDH水平。
  • PYR-41改善脓毒症小鼠肺微观结构,降低肺髓过氧化物酶活性、凋亡细胞数和caspase-3降解。
  • 在LPS刺激的小鼠巨噬细胞RAW264.7中,PYR-41剂量依赖性防止IκB蛋白减少并抑制TNF-α释放。
  • PYR-41恢复CLP后肺组织IκB蛋白水平,并抑制肺内IL-1β、IL-6、KC、MIP-2、COX-2和iNOS表达。

适用人群与场景

  • 雄性C57BL/6小鼠,行盲肠结扎穿刺(CLP)诱导脓毒症。
  • 小鼠巨噬细胞RAW264.7,经脂多糖刺激。

处置流程与药物剂量

  • CLP造模后立即静脉注射PYR-41 5 mg/kg(溶于二甲基亚砜/生理盐水)或等体积溶剂对照。
  • CLP后20小时检测血清细胞因子和器官损伤标志物,评估肺组织学与分子指标。
  • 观察10天生存率。

研究设计与关键结果

  • 研究类型:动物实验(小鼠脓毒症模型)与细胞实验。
  • 细胞实验:LPS刺激后4小时,PYR-41剂量依赖性防止IκB蛋白水平下降并抑制TNF-α释放。
  • 动物实验:雄性C57BL/6小鼠行CLP诱导脓毒症,术后立即静脉注射PYR-41(5 mg/kg)或溶剂。
  • CLP后20小时,PYR-41显著降低血清TNF-α、IL-1β、IL-6及AST、ALT、LDH水平。
  • PYR-41显著改善肺微观结构,降低肺髓过氧化物酶活性、凋亡细胞数和caspase-3降解。
  • PYR-41恢复CLP后肺组织降低的IκB蛋白水平。
  • PYR-41抑制肺内IL-1β、IL-6、KC、MIP-2、COX-2和iNOS表达。
  • PYR-41将脓毒症小鼠10天生存率从42%显著提高至83%。

证据类型、等级与局限

  • 证据类型:动物实验与体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,靶向泛素化以抑制NF-κB活化可能是脓毒症治疗的潜在策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

During sepsis, systemic inflammation is observed and is associated with multiple organ failure. Activation of NF-κB is crucial for inducing inflammation, which is controlled by degradation of inhibitor molecules (IκB). The ubiquitination proteasome pathway is responsible for the regulation of protein turnover. In this study, we hypothesized that administration of 4[4-(5-nitro-furan-2-ylmethylene)-3, -dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (PYR-41), an inhibitor of ubiquitination, could reduce inflammation and organ injury in septic mice. PYR-41 prevented the reduction of IκB protein levels and inhibited release of tumor necrosis factor (TNF)-α in mouse macrophage RAW264.7 cells at 4 h after lipopolysaccharide stimulation dose-dependently. Male C57BL/6 mice were subjected to cecal ligation and puncture (CLP) to induce sepsis. PYR-41 (5 mg/kg) or dimethyl sulfoxide in saline (vehicle) was injected intravenously immediately after CLP. At 20 h after CLP, PYR-41 treatment significantly decreased serum levels of proinflammatory cytokines (TNF-α, interleukin [IL]-1β, and IL-6) and organ injury markers (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase). PYR-41 significantly improved microscopic structure, and reduced myeloperoxidase activity, number of apoptotic cells and caspase-3 degradation in the lungs of septic mice. The reduced protein levels of IκB in the lungs after CLP were restored by PYR-41 treatment. PYR-41 inhibited the expression of cytokines (IL-1β and IL-6), chemokines (keratinocyte-derived chemokine and macrophage inflammatory protein 2), and inflammatory mediators (cyclooxygenase-2 and inducible nitric oxide synthase) in the lungs of septic mice. Importantly, PYR-41 significantly increased 10-day survival in septic mice from 42% to 83%. Therefore, targeting ubiquitination by PYR-41 to inhibit NF-κB activation may represent a potential strategy of sepsis therapeutics.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Matsuo S, Sharma A, Wang P, et al. PYR-41, A Ubiquitin-Activating Enzyme E1 Inhibitor, Attenuates Lung Injury in Sepsis. Shock. 2018. PMID: 28661933. doi:10.1097/SHK.0000000000000931

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。